Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of AZD6234 in Overweight or Obese Healthy Subjects
NCT05511025Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of lenbelintide in Overweight and obesity (8 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of participants with AEs and Serious Adverse Events (SAE). Started Sep 2022; status: completed.
02
Drugs
lenbelintide
03
Conditions
Overweightobesity
Beyond the preview
Go deeper on NCT05511025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05511025.